Drug Trial Radar · NCT00337779
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
Last checked: Nov 20, 2026Latest source record: Oct 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,155
Actual
Start
Aug 2006
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Jun 16, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of R-R MS. GA is an immunomodulating drug that has anti inflammatory and neuroprotective properties. The study treatment duration is 12 months.
Conditions
- Relapsing Remitting Multiple Sclerosis
Interventions
Glatiramer Acetate (GA) 40 mgDrug
Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
glatiramer acetate 20 mgDrug
Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).Time frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.